This case deals with the initiation challenges of a medium sized company (under $1 billion) in an emerging market (India), particularly the challenges of product development and commercialization. The management has to decide how exactly to proceed with a promising innovative convention for oral insulin - a bright therapeutic area both when it comes to fiscal returns together with societal impact. The corporation had used up numerous years of R&D in getting the drug through Phase I and Phase II trials, and was incoming the most serious stage, Phase III.
Oral Insulin Breakthrough Innovation at Biocon Case Study Solution
The case is set in 2009, a period which was punctuate with a lot of financial ambiguity. Students are requested to decide if Biocon should go ahead with Phase III, and in that case, whether it should be done globally or locally and with a partner or in isolation.
PUBLICATION DATE: August 05, 2011 PRODUCT #: W11276-PDF-ENG
This is just an excerpt. This case is about STRATEGY & EXECUTION
Related Case Solutions & Analyses:
Parkin Laboratories
Hootsuite
Pequignet: The Face of the Renaissance of French Haute Horlogerie
Ransom on the High Seas: The Case of Piracy in Somalia
HUGE and Digital Strategy
Akamai’s Edge (A)
From In-house to Joint R&D: The Way forward for Nokia Denmark
Bridge International Academies: A School in a Box
Princessa Beauty Products
Take-Two Interactive Software, Inc.
